KLK3 and prostate cancer: In a phase II study on the castration-resistant prostate cancer patients treated with docetaxel (75 mg/m2), prednisone (5 mg) and curcumin (6000 mg/day), the ORR was 100%, with 40% having PR and 60% having SD, with a median time to progression of prostate-specific antigen (PSA) of 5.8 months [175].